This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (Original) Serum cholesterol lowering agent or preventive or therapeutic agent for atherosclerosis consist of the combination of a compound represented by the following general formula (I) or pharmaceutical acceptable salts and cholesterol biosynthesis inhibitors and/or fibrate-type cholesterol lowering agents,



---------- (I)

wherein A_1, A_3 and A_4 are hydrogen atom, halogen atom, alkyl group having one to five carbon atoms, alkoxy group having one to five carbon atoms, $-COOR_1$, a group represented by following formula (b)



---------- (b)

wherein R_1 is hydrogen atom or alkyl group having one to five carbon atoms,

or a group represented by following formula (a)



---------- (a)

wherein R_2 is $-CH_2OH$ group, $-CH_2OC(O)-R_1$ group or $-CO_2-R_1$ group; R_3 is -OH group or $-OC(O)-R_1$ group; R_4 is $-(CH_2)_kR_5(CH_2)_l-$, wherein k and l are an integer of 0 or more than 1; k + l is 10 or fewer integer, and R_4 group binds to tetrahydropyran ring by C-C bond, further, R_5 means single bond (-), $-CH=CH-$, $-OCH_2-$, carbonyl group or $-CH(OH)-$, and more than one of A_1, A_3 and A_4 in formula (I) must be the group in above-mentioned formula (a), A_2 is alkyl chain having one to five carbon atoms, alkoxy chain having one to five carbon atoms, alkenyl chain having one to five carbon atoms, hydroxyl alkyl chain having one to five carbon atoms or carbonyl alkyl chain having one to five carbon atoms. n, p, q or r are 0, 1 or 2.

2. (Original) Serum cholesterol lowering agent or preventive or therapeutic agent for atherosclerosis describe in claim 1 consist of the mixture of a compound represented by the above general formula (I) or pharmaceutical acceptable salts and cholesterol biosynthesis inhibitors and/or fibrate-type cholesterol lowering agents.

3. (Original) Serum cholesterol lowering agent or preventive or therapeutic agent for atherosclerosis formed a kit by single packaging a container containing a compound represented by the above general formula (I) or pharmaceutical acceptable salts and a container containing cholesterol biosynthesis inhibitor and/or fibrate-type cholesterol lowering agents.

4. (Currently amended) Serum cholesterol lowering agent or preventive or therapeutic agent for atherosclerosis according to ~~anyone of claims~~ claim 1~~, 2 and 3~~ consist of a compound which the above-mentioned general formula (I) is the following formula.



5. (Currently amended) Serum cholesterol lowering agent or preventive or therapeutic agent for atherosclerosis according to ~~anyone of claims~~ claim 1~~, 2 and 3~~ consist of a compound which the above-mentioned general formula (I) is the following formula.



6. (Currently amended) Serum cholesterol lowering agent or preventive or therapeutic agent for atherosclerosis according to ~~anyone of claims~~ claim 1~~-5~~ characterized by the use of the cholesterol biosynthesis inhibitors which is at least one sort chosen from the group consisting of HMG-CoA reductase inhibitors, squalene synthase inhibitors and squalene epoxydase inhibitors.

7. (Currently amended) Serum cholesterol lowering agent or preventive or therapeutic agent for atherosclerosis according to ~~anyone of claims~~ claim 1~~-5~~ characterized by the use of fibrate-type cholesterol lowering agents which is at least one sort chosen from the group consisting of clofibrate, bezafibrate, cinfibrate, fenofibrate, gemfibrogyl and AHL-157.

8. (Original) A dosage method of serum cholesterol lowering agent or preventive or therapeutic agent for atherosclerosis

characterized by the administration of a compound represented by the above-mentioned formula (I) or pharmaceutical acceptable salts and cholesterol biosynthesis inhibitors and/or fibrate-type cholesterol lowering agents simultaneously or consecutively.

9. (New) Serum cholesterol lowering agent or preventive or therapeutic agent for atherosclerosis according to claim 2 consist of a compound which the above-mentioned general formula (I) is the following formula.



10. (New) Serum cholesterol lowering agent or preventive or therapeutic agent for atherosclerosis according to claim 3 consist of a compound which the above-mentioned general formula (I) is the following formula.



11. (New) Serum cholesterol lowering agent or preventive or therapeutic agent for atherosclerosis according to claim 2 consist of a compound which the above-mentioned general formula (I) is the following formula.



12. (New) Serum cholesterol lowering agent or preventive or

therapeutic agent for atherosclerosis according to claim 3 consist of a compound which the above-mentioned general formula (I) is the following formula.



13. (New) Serum cholesterol lowering agent or preventive or therapeutic agent for atherosclerosis according to claim 2 characterized by the use of the cholesterol biosynthesis inhibitors which is at least one sort chosen from the group consisting of HMG-CoA reductase inhibitors, squalene synthase inhibitors and squalene epoxydase inhibitors.

14. (New) Serum cholesterol lowering agent or preventive or therapeutic agent for atherosclerosis according to claim 3 characterized by the use of the cholesterol biosynthesis inhibitors which is at least one sort chosen from the group consisting of HMG-CoA reductase inhibitors, squalene synthase inhibitors and squalene epoxydase inhibitors.

15. (New) Serum cholesterol lowering agent or preventive or therapeutic agent for atherosclerosis according to claim 4 characterized by the use of the cholesterol biosynthesis inhibitors which is at least one sort chosen from the group consisting of HMG-CoA reductase inhibitors, squalene synthase inhibitors and squalene epoxydase inhibitors.

16. (New) Serum cholesterol lowering agent or preventive or therapeutic agent for atherosclerosis according to claim 9 characterized by the use of the cholesterol biosynthesis inhibitors which is at least one sort chosen from the group consisting of HMG-CoA reductase inhibitors, squalene synthase inhibitors and squalene epoxydase inhibitors.

17. (New) Serum cholesterol lowering agent or preventive or therapeutic agent for atherosclerosis according to claim 10 characterized by the use of the cholesterol biosynthesis inhibitors which is at least one sort chosen from the group consisting of HMG-CoA reductase inhibitors, squalene synthase inhibitors and squalene epoxydase inhibitors.

18. (New) Serum cholesterol lowering agent or preventive or therapeutic agent for atherosclerosis according to claim 5 characterized by the use of the cholesterol biosynthesis

inhibitors which is at least one sort chosen from the group consisting of HMG-CoA reductase inhibitors, squalene synthase inhibitors and squalene epoxydase inhibitors.

19. (New) Serum cholesterol lowering agent or preventive or therapeutic agent for atherosclerosis according to claim 11 characterized by the use of the cholesterol biosynthesis inhibitors which is at least one sort chosen from the group consisting of HMG-CoA reductase inhibitors, squalene synthase inhibitors and squalene epoxydase inhibitors.

20. (New) Serum cholesterol lowering agent or preventive or therapeutic agent for atherosclerosis according to claim 12 characterized by the use of the cholesterol biosynthesis inhibitors which is at least one sort chosen from the group consisting of HMG-CoA reductase inhibitors, squalene synthase inhibitors and squalene epoxydase inhibitors.

21. (New) Serum cholesterol lowering agent or preventive or therapeutic agent for atherosclerosis according to claim 2 characterized by the use of fibrate-type cholesterol lowering agents which is at least one sort chosen from the group consisting of clofibrate, bezafibrate, cinfibrate, fenofibrate, gemfibrogyl and AHL-157.

22. (New) Serum cholesterol lowering agent or preventive or therapeutic agent for atherosclerosis according to claim 3 characterized by the use of fibrate-type cholesterol lowering agents which is at least one sort chosen from the group consisting of clofibrate, bezafibrate, cinfibrate, fenofibrate, gemfibrogyl and AHL-157.

23. (New) Serum cholesterol lowering agent or preventive or therapeutic agent for atherosclerosis according to claim 4 characterized by the use of fibrate-type cholesterol lowering agents which is at least one sort chosen from the group consisting of clofibrate, bezafibrate, cinfibrate, fenofibrate, gemfibrogyl and AHL-157.

24. (New) Serum cholesterol lowering agent or preventive or therapeutic agent for atherosclerosis according to claim 9 characterized by the use of fibrate-type cholesterol lowering agents which is at least one sort chosen from the group consisting of clofibrate, bezafibrate, cinfibrate, fenofibrate, gemfibrogyl and AHL-157.

25. (New) Serum cholesterol lowering agent or preventive or therapeutic agent for atherosclerosis according to claim 10 characterized by the use of fibrate-type cholesterol lowering agents which is at least one sort chosen from the group

consisting of clofibrate, bezafibrate, cinfibrate, fenofibrate, gemfibrogyl and AHL-157.

26. (New) Serum cholesterol lowering agent or preventive or therapeutic agent for atherosclerosis according to claim 5 characterized by the use of fibrate-type cholesterol lowering agents which is at least one sort chosen from the group consisting of clofibrate, bezafibrate, cinfibrate, fenofibrate, gemfibrogyl and AHL-157.

27. (New) Serum cholesterol lowering agent or preventive or therapeutic agent for atherosclerosis according to claim 11 characterized by the use of fibrate-type cholesterol lowering agents which is at least one sort chosen from the group consisting of clofibrate, bezafibrate, cinfibrate, fenofibrate, gemfibrogyl and AHL-157.

28. (New) Serum cholesterol lowering agent or preventive or therapeutic agent for atherosclerosis according to claim 12 characterized by the use of fibrate-type cholesterol lowering agents which is at least one sort chosen from the group consisting of clofibrate, bezafibrate, cinfibrate, fenofibrate, gemfibrogyl and AHL-157.